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Abstract
Background The randomised, double-blind, placebo-controlled Systolic Hypertension in Europe trial
(Syst-Eur 1) proved that blood pressure (BP) lowering therapy starting with nitrendipine reduces the risk
of cardiovascular complications in elderly patients with isolated systolic hypertension. In an attempt to
confirm the safety of long-term antihypertensive therapy based on a dihydropyridine, the Syst-Eur patients
remained in open follow-up after the end of Syst-Eur 1. This paper presents the second progress report of
this follow-up study (Syst-Eur 2). It describes BP control and adherence to study medications.
Methods After the end of Syst-Eur 1 all patients, treated either actively or with placebo, were invited
either to continue or to start antihypertensive treatment with the same drugs as previously used in the
active treatment arm. In order to reach the target BP (sitting SBP <150 mmHg), the first line agent,
nitrendipine, could be associated with enalapril and/or hydrochlorothiazide.
Results Of the 3787 eligible patients, 3516 (93%) entered Syst-Eur 2. At the last available visit, 72%
of the patients were taking nitrendipine. SBP/DBP at entry in Syst-Eur 2 averaged 160/83 mmHg in
the former placebo group and 151/80 mmHg in the former active-treatment group. At the last follow-
up visit SBP/DBP in the patients previously randomised to placebo or active treatment had decreased
by 16/5 mmHg and 7/5 mmHg, respectively. The target BP was reached by 74% of the patients.
Conclusion Substantial reductions in systolic BP may be achieved in older patients with isolated
systolic hypertension with a treatment strategy starting with the dihydropyridine calcium-channel
blocker, nitrendipine, with the possible addition of enalapril and/or hydrochlorothiazide.
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Introduction
The double-blind, placebo-controlled Systolic Hypertension in
Europe (Syst-Eur) trial proved that antihypertensive treatment
starting with nitrendipine reduced the risk of cardiovascular
complications in older patients with isolated systolic hyper-
tension [1,2]. Similar findings were obtained in two placebo-
controlled trials in China [3,4], in which antihypertensive
treatment was also initiated with a dihydropyridine calcium-
channel blocker. For a variety of ethical and documentary
reasons, it was decided to extend the Syst-Eur trial into an
open-label, active treatment, follow-up study in the same pop-
ulation and based upon the original active trial medication.
The vast majority of patients volunteered to participate in this
open follow-up study, Systolic Hypertension in Europe Phase
2 (Syst-Eur 2), which will last until the end of 2001. In this
article, which is the second progress report of Syst-Eur 2, we
aim to describe blood pressure (BP) control and adherence
to study medications during the first three years of follow-up
and, also, to explore whether BP control was influenced by
diabetic status, or smoking/drinking habits.
Methods
Design of the Syst-Eur 2 study
The protocols of the Syst-Eur 1 [1] and Syst-Eur 2 [5] studies
were approved by the Ethics Committees of the University of
Leuven and by the participating centres, and implemented
according to the principles outlined in the Helsinki declaration
[6]. Patients were eligible for the Syst-Eur 1 trial if they were
at least 60 years of age and had a sitting systolic BP within
the range 160–219 mmHg and a diastolic BP below
95 mmHg (with a systolic pressure of 140 mmHg or higher
while they were standing). Patients were recruited from 198
centres in 23 countries across Western and Eastern Europe.
Eligible patients were stratified by centre, sex and previous
cardiovascular complications, and were randomised to
double-blind treatment with either active medication or
placebo. After the termination of Syst-Eur 1 [1] in Spring
1997, all the patients who were still in follow-up were
requested to continue or to start antihypertensive therapy with
the same drugs as previously used in the active-treatment arm.
The goal of antihypertensive treatment during Syst-Eur 2 is to
lower the sitting systolic BP (average of two readings,
obtained after rest for five minutes) to less than 150 mmHg.
The target pressure should be achieved by the stepwise titra-
tion of nitrendipine (10–40 mg/day), the first-line study med-
ication, with the possible addition of either enalapril
(5–20 mg/day) or hydrochlorothiazide (12.5–25 mg/day), or
both of these drugs. If side effects occur during monotherapy
with nitrendipine, the daily dose should first be back-titrated.
If side effects persist at this lower dose, nitrendipine may be
discontinued and enalapril started. Similarly, the second-line
medication may be withdrawn because of side effects, and
hydrochlorothiazide started. The open-label study medication
may be associated with, or replaced by, any other antihyper-
tensive or cardiovascular drug if a treatment-resistant patient
requires it to reach the goal BP, or if a patient requires treat-
ment for a cardiovascular disorder.
During the first year of Syst-Eur 2, clinic visits were sched-
uled every three months; from the second year onwards,
reports are due every six months (i.e. supervised follow-up).
Patients who withdraw from the study and who no longer par-
ticipate in clinic visits, proceed to the non-supervised follow-
up, during which the investigator has to collect, at annual
intervals, information on vital status, occurrence of major
events and the use of antihypertensive medications.
Data analysis
Database management and statistical analysis were per-
formed using SAS software version 8.01 (Cary, NC, USA).
The last available BP measurements before the end of Syst-
Eur 1 were taken as the baseline pressures in Syst-Eur 2.
Baseline blood and urine tests were those obtained nearest
to 14 February 1997, the date on which Syst-Eur 1 ended.
The BP changes during follow-up were analysed using the
difference between baseline and the last available measure-
ments. Means were compared by the Student’s t-test.
Between-group proportions were compared by the chi-
square test, and within-group proportions by McNemar’s test.
Results
Study profile
A total of 4695 patients had been randomised in the Syst-Eur
trial (Fig. 1). At the termination of Syst-Eur 1 there had been
282 deaths (6.0%), while 124 patients (2.6%) without any
report within the year before the trial stopped were counted
as lost to follow-up [2]. These patients were not, therefore,
eligible for further follow-up in Syst-Eur 2. Furthermore, on
February 14,1997, 502 patients (10.6%) had already pro-
ceeded to non-supervised follow-up. Of the remaining 3787
patients who were eligible for further follow-up in Syst-Eur 2,
3516 (92.8%) participated. On June 15, 2000, 3021 of the
3516 patients enrolled in Syst-Eur 2, were still in follow-up,
277 had proceeded to non-supervised follow-up and 158
had died. Sixty patients without any report within the last
18 months were counted as lost to follow-up (Fig. 1). The
median follow-up in Syst-Eur 2 was 37 months (range
0.3–40 months). The number of patient-years of follow-up in
Syst-Eur 2 totalled 9988.
Patient characteristics
Table 1 presents the characteristics of the 3516 patients at
entry into Syst-Eur 1 and at baseline into Syst-Eur 2. At ran-
domisation, patients in the placebo and active-treatment
groups were similar for the distribution of sex, age, BP, pulse
rate, body-mass index, serum cholesterol, the use of tobacco
and alcohol, and previous cardiovascular complications.
Median follow-up in Syst-Eur 1 was 1.7 years. At entry into
Syst-Eur 2 the 2340 women and 1176 men were, on
average, 71.2 ± 6.3 years old. As expected, BP at entry into
Syst-Eur 2 was higher in the former placebo group as com-
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Figure 1
Profile of patients in the Syst-Eur study. Patients without any report within the last year were classified as lost-to-follow-up in Syst-Eur 1. Patients
without any report within the last 18 months were counted as lost to follow-up in Syst-Eur 2. DB, double-blind; NSOF, non-supervised open follow-
up; SOF, supervised open follow-up.
Table 1
Patient characteristics at baseline and at the end of the Syst-Eur 1 trial
Baseline Syst-Eur 1 Baseline Syst-Eur 2
Characteristic Placebo Active Placebo† Active†
Number 1691 1825 1691 1825
Female sex 1121 (66.3%) 1219 (66.8%) 1121 (66.3%) 1219 (66.8%)
Age (years) 69.0 ± 6.0 69.0 ± 5.8 71.1 ± 6.4++ 71.2 ± 6.3++
Sitting systolic blood pressure (mmHg) 173.4 ± 9.5 173.3 ± 9.4 160.4 ± 16.2++ *** 151.0 ± 14.6++
Sitting diastolic blood pressure (mmHg) 85.6 ± 5.7 85.7 ± 5.7 83.4 ± 7.7++ *** 79.6 ± 7.8++
Sitting heart rate (beats per minute) 72.8 ± 8.0 72.8 ± 7.9 72.5 ± 9.1 * 73.1 ± 8.9
Standing systolic blood pressure (mmHg) 168.3 ± 11.5 167.9 ± 11.9 157.6 ± 16.6++ *** 148.2 ± 15.5++
Standing diastolic blood pressure (mmHg) 87.6 ± 7.6 87.6 ± 7.6 85.1 ± 9.2++ *** 81.6 ± 8.9++
Body-mass index (kg/m2) 27.3 ± 4.0 27.3 ± 4.2 27.0 ± 4.0++ 27.1 ± 4.2++
Total cholesterol (mmol/l) 6.0 ± 1.2 6.0 ± 1.2 5.9 ± 1.1++ 5.8 ± 1.1++
High-density-lipoprotein cholesterol (mmol/l) 1.40 ± 0.46 1.42 ± 0.48 1.36 ± 0.40+ * 1.40 ± 0.47
History of stroke 18 (1.1%) 20 (1.1%) 39 (2.3%)++ 34 (1.9%)++
History of myocardial infarction 61 (3.6%) 62 (3.4%) 73 (4.3%)++ ** 71 (3.9%)++
Diabetes mellitus 170 (10.1%) 189 (10.4%) 205 (12.1%)++ 235 (12.9%)++
Current smokers 106 (6.3%) 121 (6.6%) 71 (4.2%)++ 86 (4.7%)++
Abstaining from alcohol 1227 (72.6%) 1311 (71.9%) 1324 (78.3%)++ 1388 (76.1%)++
<1 unit alcohol per day 282 (16.7%) 337 (18.4%) 225 (13.3%)++ 261 (14.3%)++
≥1 unit alcohol per day 181 (10.7%) 176 (9.7%) 142 (8.4%)++ 175 (9.6%)
Values are given as mean ± SD or number of patients (%). † Indicates patients formerly randomised to placebo and active treatment. Significance
of between-group differences: *P <0.05; **P <0.01; ***P <0.001. Significance of within-group changes: +P <0.01; ++P <0.001.
pared with the former active-treatment group. Body-mass index
(0.23 ± 1.56 kg/m2) and total cholesterol (0.17 ± 0.91 mmol/l)
had decreased (P < 0.001) during Syst-Eur 1, but to a similar
extent in the placebo and active-treatment groups. A total of
85 patients stopped smoking and 15 started smoking during
Syst-Eur 1. Only 38 patients had experienced a nonfatal
stroke during Syst-Eur 1 and 25 had a nonfatal myocardial
infarction. A total of 359 (10.2%) patients had diabetes melli-
tus at randomisation and another 81 patients (2.3 %) devel-
oped diabetes during the Syst-Eur 1 trial.
Treatment
At the end of Syst-Eur 1, significantly fewer patients
(P < 0.001) in the active treatment group than in the control
group had proceeded to combined treatment with various
double-blind medications. Also, fewer patients (P < 0.001)
randomised to active treatment were in open follow-up
(Table 2). At the last visit in Syst-Eur 1, 1514 (83.0%)
patients of the active treatment group took nitrendipine, either
in monotherapy (n = 1065; 58.4%) or in combination with
enalapril and/or hydrochlorothiazide (n = 449; 24.6%). The
average daily doses of the active double-blind medications
were 28.1 ± 12.1 mg for nitrendipine (n = 1514),
13.6 ± 6.1 mg for enalapril (n = 557), and 21.4 ± 6.8 mg for
hydrochlorothiazide (n = 220). Of the 235 diabetic patients
randomised to active treatment, 197 (83.8%) took nitrendip-
ine either in monotherapy (n = 136; 57.9%) or in combination
with the second and/or the third line drug (n = 61; 26.0%).
At the last visit in Syst-Eur 2, the number of patients proceed-
ing to combined treatment with the various study drugs was
similar in the former placebo (40.6%) and active-treatment
(43.8%) groups (Table 3). Of the 1691 patients previously
randomised to placebo, 1194 (70.6%) took nitrendipine,
either in monotherapy (n = 596; 35.2%) or in combination
with enalapril and/or hydrochlorothiazide and/or other antihy-
pertensive drugs (n = 598; 35.4%). Among the 1825
patients of the former active-treatment group, 1328 (72.8%)
took nitrendipine, either alone (n = 676; 37.0%), or in combi-
nation with other drugs (n = 652; 35.7%) (Table 3). At the
last available visit, the average daily doses of the study drugs
in the patients formerly randomised to placebo were
31.0 ± 11.1 mg (n = 1194) for nitrendipine, 15.1 ± 5.7 mg for
enalapril (n = 693), and 24.1 ± 9.7 mg (n = 326) for hydro-
chlorothiazide. In the patients previously randomised to active
treatment, these doses were 31.2 ± 11.2 mg (n = 1328),
15.3 ± 5.8 mg (n = 823), and 23.7 ± 8.2 mg (n = 424)
respectively.
At the last follow-up visit, the proportion of patients taking
nitrendipine was 68.6% in the diabetic patient group, 72.4 %
in the nondiabetic group, 78.3% in the patients who smoke,
71.7% in the nonsmokers group, 77.5% in the patients con-
suming at least 1 unit of alcohol per day, and 71.4% in the
group of nondrinkers or very mild drinkers.
Blood pressure
At entry in Syst-Eur 2, the mean sitting systolic BP in the
patients formerly randomised to placebo was
160.4 ± 16.2 mmHg and in those of the former active-treat-
ment group it was 151.0 ± 14.6 mmHg; the corresponding
diastolic levels were 83.4 ± 7.7 mmHg and 79.6 ± 7.8 mmHg
(Table 1). Of the 3516 patients, 1683 in the former placebo
group and 1819 in the former active treatment group had
their BP measured at least once during Syst-Eur 2. At the last
available visit in Syst-Eur 2, in the patients of the former
control group, the sitting blood pressure had fallen by
15.7 ± 18.7 mmHg systolic and by 5.1 ± 16.7 mmHg dias-
tolic; in the patients previously randomised to active treat-
ment, the corresponding BP reductions were
7.5 ± 16.7 mmHg systolic and 2.4 ± 11.8 mmHg diastolic,
respectively (Fig. 2).
The between-group differences in systolic and diastolic BP
(placebo minus active treatment group) at entry in Syst-Eur 2
were 9.4 mmHg (95% confidence interval [CI]
8.4–10.4 mmHg) and 3.8 mmHg (95% CI 3.3–4.3 mmHg),
respectively. At the last visit, these differences were
1.3 mmHg (95% CI 0.4–2.2 mmHg) and 1.2 mmHg (95% CI
0.3–2.1 mmHg) (Fig. 2).
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Table 2
Treatment status at the termination of the double-blind Syst-
Eur 1 trial
Active 
Placebo* treatment*
Total number 1691 1825
Still in double-blind follow-up 1487 (88%) 1718 (94%)
No study drugs 25 (1%) 28 (2%)
Nitrendipine/placebo only 665 (39%) 1065 (58%)
Study medication other than 797 (47%) 625 (34%)
nitrendipine
Drugs taken†
Nitrendipine/placebo 1396 (83%) 1514 (83%)
Enalapril/placebo 757 (45%) 557 (31%)
Hydrochlorothiazide/placebo 399 (24%) 220 (12%)
Open-label antihypertensive 20 (1%) 13 (1%)
drugs‡
Supervised open follow-up 204 (12%) 107 (6%)
No antihypertensive drugs 43 (3%) 25 (1%)
Open-label antihypertensive drugs 142 (8%) 74 (4%)
Treatment unknown 19 (1%) 8 (0%)
*Indicates patients formerly randomised to placebo or active treatment.
†Because many patients were on combined treatment, numbers do not
add up. ‡To bridge medical emergencies without having to break the
code, antihypertensive drugs could be prescribed during the double-
blind trial for up to 3 consecutive months.
At baseline in Syst-Eur 2, 25.7 % of the patients randomised
to placebo and 50.5% of those in the active-treatment group,
had a sitting systolic BP less than 150 mmHg (P < 0.001). At
the last visit in Syst-Eur 2 these proportions were 71.9% and
76.0%, respectively (P = 0.006) (Fig. 3). The percentage of
patients reaching the target BP was somewhat lower
(P = 0.02) in the diabetic (69.3%) as compared to the nondi-
abetic patients (74.7%). By contrast, BP control was similar
in patients consuming at least 1 unit of alcohol per day
(74.6%) as compared to the other patients (74.0%). The pro-
portion of patients reaching goal BP was similar in smokers
(75.8%) and nonsmokers (73.9%).
In the former placebo group, 3.3% of the patients reaching
the target BP were not taking any antihypertensive drugs,
36.9% were on nitrendipine only, 44.8% were taking enalapril
and/or hydrochlorothiazide, and in 15.0% the study medica-
tion was associated with or replaced by other antihyperten-
Current Controlled Trials in Cardiovascular Medicine    December 2001    Vol 2 No 6 Thijs et al.
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Figure 2
Average sitting systolic and diastolic blood pressures at baseline and
during follow-up in Syst-Eur 2. Open and closed symbols indicate the
patients formerly randomised to placebo or active treatment,
respectively. The total number of patients at each follow-up visit is
presented separately for the 2 previous arms of the trial.
sive drugs. In the former active treatment group these per-
centages were 2.2%, 40.4%, 44.1% and 13.3%, respec-
tively.
The distribution of the last available systolic BP was as
follows: 2% <120 mmHg; 9% between 120 and 129 mmHg;
27% between 130 and 139 mmHg; 36% between 140 and
149 mmHg; 14% between 150 and 159 mmHg; 12%
>160 mmHg (Fig. 4). Fourteen percent of the patients
achieved a diastolic BP < 70 mmHg, 47% between 70 and
79 mmHg, 33% between 80 and 89 mmHg and 6%
> 90 mmHg.
Discussion
This paper describes BP control and compliance with study
medications in 3516 older patients with isolated systolic
hypertension who are being followed in Syst-Eur 2 [5]. We
found that substantial reductions in systolic BP could be
achieved with a treatment strategy starting with the dihy-
dropyridine calcium-channel blocker, nitrendipine, with the
possible addition of enalapril and/or hydrochlorothiazide. At
the last available follow-up visit, 74% of the patients had
reached a systolic BP level below the target of 150 mmHg
and an additional 14% achieved a systolic pressure below
160 mmHg. During Syst-Eur 1, systolic BP decreased on
average by 22 mmHg in the active-treatment group and by
13 mmHg in the placebo group. During Syst-Eur 2, systolic
BP further decreased by 7 mmHg and 15 mmHg, respec-
tively. Part of the additional decrease in BP in the former
active-treatment group might be due to the early termination
of the Syst-Eur trial. Indeed, 261 (7.4%) of the patients par-
ticipating in Syst-Eur 2 had been randomised less than
6 months before the end of Syst-Eur 1. In these patients, titra-
tion of study medication was probably not yet completed
when the trial stopped in February 1997. Indeed, 85% of the
active-treatment patients who were randomised less then
6 months before the end of Syst-Eur 1 were still on monother-
apy with nitrendipine. Another more likely explanation is that
the evidence produced by the Syst-Eur trial [1,2] motivated
the investigators to further up-titrate treatment to achieve
optimal BP control and greater risk reduction in their patients.
From the start of the Syst-Eur trial, the Data Monitoring Com-
mittee carefully monitored BP control. At yearly intervals all
centres received a list of patients who had not yet attained
the target BP, together with information on the amount of
study medications that these patients were taking. In addition,
centres monitoring at least 10 patients received a graph
showing the change of BP over time broken down by treat-
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Figure 3
Proportion of patients reaching a systolic blood pressure below the
target of 150 mmHg at baseline and during follow-up in Syst-Eur 2.
Open and closed symbols indicate the patients formerly randomised to
placebo or active treatment, respectively. The total number of patients
at each follow-up visit is presented separately for the 2 previous arms
of the trial.
Figure 4
Cumulative distributions of systolic blood pressure at the end of 
Syst-Eur 1 in the placebo and active treatment group and at the last
available visit in Syst-Eur 2. The vertical line indicates the goal systolic
pressure of 150 mmHg.
ment group. BP control was personally discussed with the
investigators at all of the 106 site visits and at the nine meet-
ings for investigators that were held between 1989 and
2000. This quality control program probably contributed to
the high rate of BP control currently achieved.
Syst-Eur 2 is an open study that allows the use of antihyper-
tensive treatment other than the study drugs [5]. Nonethe-
less, a high level of adherence to the study drugs was
observed throughout the three initial years of follow-up. At the
last available follow-up visit, 72% of the patients were taking
nitrendipine and an additional 15% were taking study drugs
other than nitrendipine. The withdrawal rate in Syst-Eur 2 was
also very low. Of the 3358 patients who were still alive on
June15, 2000, 90% were still being followed in supervised,
open follow-up and another 8.2% in non-supervised, open
follow-up. Only 1.8% of the patients without any report within
the last 18 months were counted as lost to follow-up.
Guidelines from the US Joint National Committee [7], the
World Health Organization [8], the British Hypertension
Society [9] and the Canadian Medical Association [10] all
recommend an optimal target systolic BP of 140 mmHg in
older hypertensive patients. These guidelines were published
only after the protocol of Syst-Eur 1 was written (1989). Syst-
Eur 2 was an extension of the Syst-Eur 1 trial and it was
decided that the protocols of these two studies should be as
similar as possible. The World Health Organization and the
British Hypertension Society based their advice mainly on the
results of the Hypertension Optimal Treatment (HOT) trial
[11]. Comparisons between the three randomised BP target
groups (diastolic BP ≤90, ≤85 or ≤80 mmHg), however,
showed no differences in cardiovascular outcomes in nondia-
betic patients. Based on a Poisson model relating achieved
BP to outcome, the optimal BP for reduction of major cardio-
vascular events was reported to be 139/83 mmHg. Neverthe-
less, patients whose BPs were below 150/90 mmHg were
not apparently disadvantaged [9]. In the present population,
the threshold of 140 mmHg proposed by the expert commit-
tees was reached by 38% of the patients. Because the target
BP in the Syst-Eur trial was 150 mmHg, no efforts were
undertaken to further lower the BP below 140 mmHg. More-
over, several experts had advised that the diastolic BP should
not be lowered much below 70 mmHg [12–14]. In the
present study, 14% of the patients had a diastolic BP below
this threshold.
Comparison of BP control between various trials is difficult
because of the large differences in the BP entry criteria, treat-
ment targets, antihypertensive drugs used and definitions of
achieved BP. In the HOT trial [11], systolic BP decreased on
average by 26 mmHg, 28 mmHg and 30 mmHg in the dias-
tolic BP target groups of ≤90 mmHg, ≤85 mmHg, and
< 80 mmHg, respectively. In our study the overall reduction in
systolic BP of 29 mmHg was comparable to the changes
obtained in the middle and low BP target groups of the HOT
trial. Because systolic BP at randomisation was, on average,
3.5 mmHg lower in the HOT trial as compared with the Syst-
Eur trial, however, the on-treatment systolic pressure in the
Syst-Eur trial (144 mmHg) was similar to the systolic pres-
sure achieved in the highest BP target group of the HOT trial
(144 mmHg). In the Swedish Trial in Old Patients with Hyper-
tension-2 (STOP-Hypertension-2) [15], patients aged
70–84 years, with moderate to severe hypertension (systolic
BP >180 mmHg or diastolic BP >105 mmHg) were randomly
assigned conventional antihypertensive drugs (diuretics or β-
blockers) or newer drugs (calcium-channel blockers or
angiotensin-converting enzyme inhibitors). Target BP was
160/95 mmHg. Systolic BP decreased from 194 mmHg to
158 mmHg in the conventional drug group, 159 mmHg in the
angiotensin-converting enzyme inhibitor group and
159 mmHg in the group taking calcium-channel blockers. In
the Nordic Diltiazem (NORDIL) study [16] patients aged
50–74 years with a diastolic BP of at least 100 mmHg were
randomised. The treatment target was a diastolic BP below
90 mmHg. Systolic BP was reduced from 173 mmHg to
155 mmHg in the diltiazem group and to 152 mmHg in the
groups on older drugs. The percentages of patients reaching
the target BP in the HOT, STOP-Hypertension-2 and
NORDIL trials were not reported.
The double-blind International Nifedipine GITS study
(INSIGHT) [17] recruited patients between 55 and 80 years
old with hypertension (BP ≥150/95 mmHg, or systolic BP
≥160 mmHg) and with at least one additional cardiovascular
risk factor. Patients were randomised to nifedipine GITS or
co-amilozide. In both treatment groups, systolic BP fell from
173 mmHg to 138 mmHg. Between 54% and 59% of the
patients reached the target BP, which was defined as a
decrease in BP by at least 20/10 mmHg to a level below
140/90 mmHg. In the INSIGHT study, however, an intention-
to-treat analysis of BP responses was not presented. Finally,
in the Antihypertensive and Lipid-Lowering Treatment to
Prevent Heart Attack Trial (ALLHAT) [18], hypertensive
patients (systolic BP ≥140 mmHg or diastolic BP
≥90 mmHg) aged ≥55 years with at least one additional risk
factor, were randomised to double-blind treatment with four
types of antihypertensive drugs. Systolic BP fell from
145 mmHg at baseline to 136 mmHg at two years in the
chlorthalidone group and to 138 mmHg in the doxazosin
group. The percentages of patients reaching the target BP
(<140 mmHg systolic and < 90 mmHg diastolic) were 61%
and 54% respectively.
Conclusion
On June 15, 2000, 90% of the patients entering Syst-Eur 2 in
1997 were still being followed in supervised, open follow-up
and 72% of the patients were still on nitrendipine as first-line
treatment. 74% of the patients achieved a systolic BP below
the target of 150 mmHg. The main results of the Syst-Eur 2
study will be reported in the year 2002. Additional information
can be found on the trial web site [20].
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